用含霍乱毒素A2/B的载体在大肠杆菌中表达弓形虫主要表面抗原P30

目的：克隆并表达含有弓形虫P30抗原及霍乱毒素A2／B亚基基因的原核表达载体，为弓形虫疫苗的研究奠定基础。方法：应用PCR方法扩增出P30基因片段后，克隆入含有霍乱毒素A2／B亚基基因的表达质粒pUAB024，在大肠杆菌JM109(DE3)中表达融合蛋白。通过SDS-PAGE电泳及Western blotting进行检测鉴定。结果：电泳证明质粒构建正确，SDS-PAGE显示经IPTG诱导可以产生特异性条带，Western blotting进一步证实该条带为P30-CTA2／B融合蛋白。结论：表达载体pUAB024-P30可有效表达特异性的融合弓形虫抗原蛋白P30-CTA2B。     

幽门螺杆菌vacA毒性片段与cagA融合基因的构建与表达

目的　构建幽门螺杆菌空泡毒素 (VacA)毒性片段和细胞毒素相关蛋白 (CagA)的融合基因 (vlc) ,在原核细胞中表达 ,为Hp双价融合蛋白候选疫苗的研究提供材料。 方法　用GeneSOEing技术将vacA毒性亚单位片段 (v)与cagA保守片段 (c)用疏水性多肽接头 (Gly4Ser) 3 进行拼接 ,构建融合基因vlc,将vlc定向插入原核表达质粒pQE30 ,经DNA测序分析确认后 ,转化E .coliDH5a ,IPTG诱导表达 ,Westernblot分析其抗原性。结果　DNA序列分析表明融合基因的连接顺序、方向正确 ,有一个碱基发生了无义突变。工程菌诱导后可表达相对分子量为 5 8× 10 3 的融合蛋白 ,与预期分子量一致 ,约占菌体总蛋白的 8%。Westernblot显示融合蛋白具有良好的抗原性。结论　融合基因vlc构建成功 ,表达的融合蛋白具有良好的抗原性 ,有望进一步进行免疫保护性机制的研究和Hp疫苗的制备。     

幽门螺杆菌外膜蛋白18的克隆表达及纯化研究

目的克隆表达幽门螺杆菌（HP）外膜蛋白,为HP的疫苗开发及诊断试剂盒的研究奠定基础。方法用PCR方法从HP临床分离株9806的染色体DNA中扩增出OMP18基因片段,将目的基因插入表达载体pQE30中,重组载体pQE30-OMP18经DNA测序鉴定后,将重组质粒转化大肠杆菌E．coli．M15,IPTG诱导表达。采用镍离子亲和层析纯化蛋白,并用SDS-PAGE和Western blot分析鉴定其表达。结果PCR扩增出长度为537bp的OMP18基因,片段测序分析其与Gen—Bank公布的核苷酸序列相似性达99％;SDS—PAGE显示,重组工程菌经IPTG诱导表达了分子量为20．0kDa的目的蛋白,占总蛋白的20％,经纯化后,目的蛋白纯度达85％以上;Western blot结果表明,该蛋白可与兔抗HP的多克隆抗血清发生特异的抗原抗体结合反应。结论成功构建了OMP18表达载体pQE30-OMP18,并在大肠杆菌中获得高效表达,为HP疫苗有效抗原筛选及诊断试剂的开发奠定基础。     

大肠杆菌O157VT2 B亚基基因的克隆与表达

目的对大肠杆菌O157VT2毒素B亚基基因进行克隆、表达与鉴定,为VT2毒素的抗原、抗体大规模制备及疾病的预防、诊断和疫苗研究打下基础。方法设计寡核苷酸引物,利用PCR技术从出血性大肠杆菌O157的染色体基因组中扩增出VT2毒素B亚基基因,连接到表达载体pET-28a以构建重组质粒。将重组质粒转入表达宿主菌BL21感受态细胞,通过IPTG诱导进行表达,对表达蛋白进行SDSPAGE电泳分析和Western检测。结果用PCR方法扩增出了预期大小的VT2B亚基基因,克隆得到重组质粒pET28aVT2B,转化后宿主菌成功表达分子量为8kD的目的蛋白,用特异抗体经Western检测该条带为阳性反应。结论目的基因成功克隆到宿主菌内,目的蛋白得到高效表达,最佳诱导时间为4h,目的蛋白表达量可达总蛋白量45.72%。     

日本血吸虫重组质粒pQE30-Sj26GST-Sj32的构建及其在大肠埃希菌BL21(DE3)中的表达

目的构建日本血吸虫重组质粒pQE30-Sj26GST-Sj32,研究该质粒在大肠埃希菌BL21(DE3)中的表达。方法超声粉碎日本血吸虫成虫,提取总RNA,通过RT-PCR扩增获Sj26GST和Sj32抗原编码基因;采用基因拼接法(gene SOEing)剪接Sj26GST和Sj32,得到Sj26GST-Sj32融合基因;将融合基因克隆至原核表达载体pQE30,构建重组质粒pQE30-Sj26GST-Sj32并转化大肠埃希菌BL21,经异丙基硫代-β-D-半乳糖苷(IPTG)诱导表达后用SDS-PAGE和Western blot对表达产物进行分析和鉴定。结果基因拼接法扩增出约1 991 bp的Sj26GST-Sj32融合基因;双酶切和PCR鉴定证实Sj26GST-Sj32融合基因成功插入pQE30中,SDS-PAGE显示表达产物为分子质量单位约为61 ku的重组蛋白,与预期结果一致,表达的蛋白约占菌体总蛋白的18%;Western blot鉴定重组蛋白能被日本血吸虫感染的兔血清识别。结论成功构建了日本血吸虫重组质粒pQE30-Sj26GST-Sj32,该质粒在大肠埃希菌BL21中获得了高效融合表达,表达的融合蛋白具有抗原特异性。     

结核分枝杆菌lhp-esat6融合基因穿梭表达载体的构建及在BCG中的表达

目的　构建能表达结核分枝杆菌早期分泌蛋白CFP10 -ESAT6融合蛋白的重组卡介苗 (recombinantBCG ,rBCG)。方法　以 pQE30 -CFP10 -ESAT6质粒为模板 ,通过PCR扩增 6 33bplhp -esat6基因 ,将该基因定向克隆到穿梭表达载体pJCH0 2中构建重组 pJCH0 2 -CFP10 -ESAT6质粒。用电穿孔法将重组质粒导入BCG菌构建rBCG ,将rBCG培养 2 3天 ,于收菌前 3天每天 4 5℃热诱导 4 5min ,对表达产物作SDS -PAGE及免疫印迹分析。结果　重组质粒 pJCH0 2 -CFP10 -ESAT6经酶切及测序证实构建成功 ,并在BCG中经热诱导成功表达出了具有CFP10及ESAT6抗原性的CFP10 -ESAT6融合蛋白。结论　成功构建能表达CFP10 -ESAT6融合蛋白的重组BCG ,为发展新型结核病疫苗奠定了基础。     

重组人神经肽Y融合蛋白的原核表达、纯化及其多克隆抗体制备与鉴定

目的：构建人神经肽Y（NPY）基因的原核表达载体,诱导表达重组蛋白,制备兔抗人NPY抗血清。方法：取已构建好且经测序确认无误的再组质粒pET28a—NPY转化大肠杆菌BL21（DE3）,IPTG诱导表达融合蛋白,并经SDS—PAGE检测和Western印迹鉴定,表达产物包涵体经Ni^2＋-NTA亲和层析纯化,以纯化后的融合蛋白pET28a—NPY为抗原免疫家兔,获得抗血清,Western blotting、ELISA法鉴定获得的抗血清。结果经IPTG诱导含有pET28a—NPY重组质粒的DE3菌,表达出重组人NPY融合蛋白。重组蛋白经Ni^2＋-NTA亲和层析进行纯化后,得到了较高纯度的融合蛋白,用纯化的融合蛋白免疫家兔制备了多克隆抗体,Western blotting、ELISA法证实多克隆抗体制备成功。结论：成功表达了人NPY蛋白并获得了其多克隆抗体,为进一步研究人NPY蛋白的功能奠定了基础。     

结核分枝杆菌Rv2352c基因的克隆表达及其抗原活性鉴定

目的构建含结核分枝杆菌(M.tb)rv2352c基因原核表达载体,经转化E.coli以表达Rv2352c融合蛋白,并研究其抗原性。方法用PCR扩增M.tb rv2352c基因,克隆入pET30a(+)质粒,构建pET30a(+):rv2352c重组质粒,阳性克隆测序验证正确后转化入表达宿主大肠杆菌BL21(DE3),经IPTG诱导Rv2352c蛋白表达。经Ni+-NTA层析柱纯化融合蛋白,通过SDS-PAGE和结核患者血清Western blot进行鉴定。将纯化的重组蛋白分别免疫家兔,制备抗Rv2352c抗血清,抗血清的效价测定采用酶联免疫吸附试验法(ELISA),取兔抗血清与纯化蛋白Rv2352c通过Western blot方法,检测抗体特异性。结果经酶切鉴定和测序分析证实rv2352c原核表达质粒构建正确,SDS-PAGE和Western blot结果显示,在45 kD处呈现单一蛋白条带。用重组蛋白Rv2352c免疫接种后可诱导出高滴度的特异性抗体。纯化蛋白通过Western blot鉴定证实为目的蛋白,有较强的免疫原性。结论成功构建原核表达重组质粒pET30a(+):rv2352c,制备和纯化的Rv2352c融合蛋白具有较好的纯度和生物学功能,为进一步研究结核病的潜在分子标志物奠定基础。     

空肠弯曲菌CadF蛋白的原核表达与产物分析

目的构建空肠弯曲菌cadF基因重组表达质粒pET30a(+)-cadF,分析其在大肠埃希菌中的表达情况及其融合蛋白的抗原性。方法用PCR方法扩增cadF基因,构建重组克隆质粒和表达质粒,经菌落PCR、双酶切和测序鉴定后在E.coli(DE3)原核表达系统中诱导表达,SDS-PAGE和飞行时间质谱鉴定表达蛋白,Western blot分析其抗原性。结果含重组表达载体pET-30a(+)-cadF中的cadF基因序列经测序证实与出发菌株cadF基因序列100%同源,并成功诱导表达CadF蛋白,Westernblot显示该CadF融合蛋白能被抗空肠弯曲菌多克隆兔血清识别。结论成功构建了空肠弯曲菌cadF基因重组表达载体,表达产物具有抗原性。     

粪肠球菌介导的细粒棘球绦虫重组Efs-Eg95-EgA31疫苗的构建、鉴定及表达北大核心CSCD

目的构建粪肠球菌(Efs)为载体的细粒棘球绦虫重组Efs-Eg95-EgA31疫苗,并研究其表达效率。方法采用电穿孔技术将重组质粒pGEX-Eg95-EgA31转化粪肠球菌ATCC47077株,构建rEfs-Eg95-EgA31疫苗,抽提质粒进行PCR扩增鉴定;经IPTG诱导后进行10%SDS-PAGE和Western blot等分析和鉴定表达产物。结果以从rEfs抽提的质粒为模板进行PCR可扩增出约1016 bp的Eg95-EgA31融合基因片段,SDS-PAGE显示表达产物为62.5 ku的重组蛋白,表达蛋白约占菌体总蛋白的11%;Western blot表明重组蛋白能被细粒棘球蚴感染的鼠血清识别。结论成功构建了细粒棘球绦虫rEfs-Eg95-EgA31疫苗,表达的融合蛋白具有特异的抗原性。     

Construction of a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaA

AIM: To construct a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaA gene and to detect its immunogenicity. METHODS: Genomic DNA of the standard H pylori strain 17 874 was isolated as the template, hpaA gene fragment was amplified by polymerase chain reaction (PCR) and cloned into pUCmT vector. DNA sequence of the amplified hpaA gene was assayed, then doned into the eukaryotic expression vector pIRES through enzyme digestion and ligation reactions. The recombinant plasmid was used to transform competent Escherichia coliDH5α, and the positive clones were screened by PCR and restriction enzyme digestion. Then, the recombinant pIRES-hpaA was used to transform LB5000 and the recombinant plasmid isolated from LB5000 was finally used to transform SL7207. After that, the recombinant strain was grown in vitro repeatedly. In order to identify the immunogenicity of the vaccine in vitro, the recombinant pIRES-hpaA was transfected to COS-7 cells using Lipofectamine~(TM)2000, the immunogenicity of expressed HpaA protein was detected with SDS-PAGE and Western blot. RESULTS: The 750-base pair hpaA gene fragment was amplified from the genomic DNA and was consistent with the sequence of H pylori hpaA by sequence analysis. It was confirmed by PCR and restriction enzyme digestion that H pylori hpaA gene was inserted into the eukaryotic expression vector pIRES and a stable recombinant live attenuated Salmonella typhimurium DNA vaccine carrying H pylori hpaA gene was successfully constructed and the specific strip of HpaA expressed by pIRES-hpaA was detected through Western blot. CONCLUSION: The recombinant attenuated Salmonella typhimurium DNA vaccine strain expressing HpaA protein with immunogenicity can be constructed and it may be helpful for further investigating the immune action of DNA vaccine in vivo.     

幽门螺杆菌hpaA基因在乳酸菌中的表达及免疫原性分析

摘要 目的 在乳酸菌中表达幽门螺杆菌(HP)hpaA基因,口服免疫小鼠后检测其免疫原性。方法 PCR方法从基因组中扩增基因hpaA,将其克隆至表达载体pNICE:sec,将重组质粒转化乳酸菌NZ9000株,筛选鉴定阳性菌落,诱导表达的hpaA蛋白用SDS-PAGE和Western blot进行鉴定。将雌性ICR(CV级)小鼠随机分为4组,分别用PBS、携带空质粒的乳酸菌、携带pNICE:sec-hpaA的乳酸菌、灭活的HP灌胃。免疫7次后检测其特异性IgG和IgA的产生。结果 扩增hpaA基因并构建了重组原核表达质粒pNICE:sec-hpaA,转化乳酸菌NZ9000后经nisin诱导可表达Mr分子量约29KD的重组蛋白,表达量约占菌体总蛋白量的9.3%,Western blot分析其能与幽门螺杆菌抗血清特异性反应,具有良好的免疫原性。携带pNICE:sec-hpaA质粒的乳酸菌刺激产生的IgG水平明显高于携带空质粒组,与灭活HP组没有明显的差异,但其刺激产生的IgA水平明显高于其它组（P<0.05）。结论 表达hpaA蛋白的乳酸菌口服免疫小鼠后,能够刺激小鼠产生特异的IgG和IgA,可作为幽门螺杆菌口服疫苗候选抗原。为乳酸菌作为抗原递送载体的研究和HP口服疫苗的开发提供一定的实验基础。     

Construction of hpaA gene from a clinical isolate of Helicobacter pylori and identification of fusion protein

AIM: To clone hpaA gene from a clinical strain of Helicobacter pylori and to construct the expression vector of the gene and to identify immunity of the fusion protein. METHODS: The hpaA gene from a clinical isolate Y06 of H.pylori was amplified by high fidelity PCR. The nucleotide sequence of the target DNA amplification fragment was sequenced after T-A cloning. The recombinant expression vector inserted with hpaA gene was constructed. The expression of HpaA fusion protein in E.coli BL21DE3 induced by IPTG at different dosages was examined by SDS-PAGE. Western blot with commercial antibody against whole cell of H.pylori as well as immunodiffusion assay with self-prepared rabbit antiserum against HpaA fusion protein were applied to determine immunity of the fusion protein. ELISA was used to detect the antibody against HpaA in sera of 125 patients infected with H.pylori and to examine HpaA expression of 109 clinical isolates of H.pylori. RESULTS: In comparison with the reported corresponding sequences, the homologies of nucleotide and putative amino acid sequences of the cloned hpaA gene were from 94.25-97.32 % and 95.38-98.46 %, respectively. The output of HpaA fusion protein in its expression system of pET32a-hpaA-BL21DE3 was approximately 40 % of the total bacterial proteins. HpaA fusion protein was able to combine with the commercial antibody against whole cell of H.pylori and to induce rabbit producing specific antiserum with 1:4 immunodiffusion titer after the animal was immunized with the fusion protein. 81.6 % of the serum samples from 125 patients infected with H.pylori (102/125) were positive for HpaA antibody and all of the tested isolates of H.pylori (109/109) were detectable for HpaA. CONCLUSION: A prokaryotic expression system with high efficiency of H.pylori hpaA gene was successfully established. The HpaA expressing fusion protein showed satisfactory immunoreactivity and antigenicity. High frequencies of HpaA expression in different H.pylori clinical strains and specific antibody production in H.pylori infected patients indicate that HpaA is an excellent and ideal antigen for developing H.pylori vaccine.     

Construction of a prokaryotic expression system of vacA gene and detection of vacA gene, VacA protein in Helicobacter pylori isolates and ant-VacA antibody in patients＇ sera

AIM: To construct a recombinant prokaryotic expression vector inserted with Helicobacter pylori vacA gene and identify the immunity of the expressed recombinant protein, and to determine prevalence of vacA-carrying/VacA expressing H pylori isolates and seroprevalence of specific ant-VacA antibody in H pylori infected patients. METHODS: Polymerase chain reaction technique was used to amplify complete vacA gene of H pylori strain NCTC11637 and to detect vacA gene in 109 H pylori isolates. The amplification product of the complete vacA gene was sequenced after T-A cloning. A recombinant expression vector inserted with a complete vacA gene fragment, named as pET32a-vacA, was constructed. Expression of the target recombinant protein VacA (rVacA) was examined by SDS-PAGE. Western blot using commercial antibodies against whole cell of H pylori and an immunodiffusion assay using self-prepared rabbit anti-rVacA antibody were applied to determine immunoreaction and antigenicity of rVacA. Two ELISA methods were established to detect VacA expression in H pylori isolates and the specific anti-VacA antibody in sera from 125 patients infected with H pylori. RESULTS: In comparison with the reported corresponding sequences, homologies of nucleotide and putative amino acid sequences of the cloned vacA gene were 99.82% and 100%, respectively. The constructed recombinant prokaryotic expression system efficiently produced rVacA. rVacA was able to combine with the commercial antibodies against whole cell of H pylori and to induce the immunized rabbit to produce specific antibody with an immunodiffusion titer of 1:4. All tested H pylori isolates carried vacA gene, but only 66.1% expressed VacA protein. Of the serum samples tested, 42.4% were positive for specific anti-VacA antibody. CONCLUSION: A prokaryotic expression system of H pylori vacA gene was successfully constructed. The expressed rVacA can be used to detect specific anti-VacA antibody in human and to prepare antiserum in animals. The high frequency of vacA gene in H pylori isolates, but with a low frequency of VacA expression and specific anti-VacA antibody in H pylori infected patients implies that VacA is not an ideal antigen for H pylori vaccine.     

Antigen epitope of Helicobacter pylori vacuolating cytotoxin A

AIM: To construct and select antigen epitopes of vacuolating cytotoxin A (VacA) for nontoxic VacA vaccine against Helicobacter pylori (H pylori ) infection. METHODS: Eleven VacA epitopes were predicted according to VacA antigenic bioinformatics. Three candidates of VacA epitope were constructed through different combined epitopes. The candidate was linked with E. coli heat-labile enterotoxin B (LTB) by a linker of 7 amino acids, and cloned into plasmid pQE-60 in which fusion LTB-VacA epitope was efficiently expressed. To test the antigencity of the candidate, 6 BALB/c mice were treated with the fusion LTB-VacA epitope through intraperitoneal injection. To explore the ability of inhibiting the toxicity of VacA,cantiserum against the candidate was used to counteract VacA that induced HeLa cells to produce cell vacuoles in vitro. RESULTS: Serum IgG against the candidate was induced in the BALB/c mice. In vitro, the three antisera against the candidate efficiently counteracted the toxicity of VacA, and decreased the number of cell vacuoles by 14.17%, 20.20% and 30.41% respectively. CONCLUSION: Two of the three candidates, LZ-VacA1and LZ-VacA2, can be used to further study the mechanism of vacuolating toxicity of VacA, and to construct nontoxic VacA vaccine against H pylori infection.     

幽门螺杆菌尿素酶B亚单位在大肠杆菌中的融合表达与鉴定

目的 通过对幽门螺杆菌（Helicobacter pylori,Hipylori)尿素酶B亚单位在大肠杆菌中表达的研究，探索其免疫反应性。方法 用高保真PCR方法扩增H.pylori ureB基因，并定向克隆人pNEB193中，然后经酶切回收后插入原核表达载体pMAL-C2X进行融合表达。采用蛋白印迹法对表达产物进行鉴定。结果 特异PCR和酶切鉴定证实融合基因ureB克隆人表达载体，SDS-PAGE结果显示ureB在大肠杆菌中以融合蛋白形式MBP-ureB高效表达，约占细胞总蛋白量的26.7%。该融合蛋白可与H.pylori阳性病人血清发生特异反应。结论 成功构建了高效表达H.pylori ureB的重组菌，为Hp基因工程疫苗的进一步研究奠定了基础。     

幽门螺杆菌GGT基因的克隆及其在大肠杆菌中的表达

目的: 克隆幽门螺杆菌( H pylori)γ-谷氨酰转肽酶(γ-glutamyl transpeptidase,GGT)基因,实现GGT基因在大肠杆菌中的表达.方法: 从胃癌患者胃黏膜组织中分离培养获得H pylori,提取其基因组DNA,对GGT基因进行PCR扩增,克隆进pMD18-T载体,酶切和测序验证,构建原核表达载体pET-28a(+)-GGT,转化大肠杆菌BL21,经IPTG诱导表达重组融合蛋白,SDS-PAGE及Western blot分析检测表达产物.结果: 成功克隆了GGT基因,经酶切和测序验证正确,成功构建了pET-28a(+)-GGT质粒,高效表达出了68 kDa的融合蛋白.结论: 在大肠杆菌中成功表达了GGT重组融合蛋白,为进一步研究GGT与线粒体介导的细胞凋亡之间的关系奠定了基础.     

Construction of a prokaryotic expression system of vacA gene and detection of vatA gene,VacA protein in Helicobacter pylori isolates and ant-VacA antibody in patients''sera

AIM: To construct a recombinant prokaryotic expression vector inserted with Helicobacter pylori vacA gene and identify the immunity of the expressed recombinant protein,and to determine prevalence of vacA-carryinglVacA expressing Hpyloriisolates and seroprevalence of specific ant-VacA antibody in H pyloriinfected patients.METHODS: Polymerase chain reaction technique was used to amplify complete vacA gene of H pyloristrain NCTC11637 and to detect vacA gene in 109 H pylori isolates. The amplification product of the complete vacA gene was sequenced after T-A cloning. A recombinant expression vector inserted with a complete vacA gene fragment, named as pET32a-vacA, was constructed. Expression of the target recombinant protein VacA (rVacA) was examined by SDSPAGE. Western blot using commercial antibodies against whole cell of H pyloriand an immunodiffusion assay using self-prepared rabbit anti-rVacA antibody were applied to determine immunoreaction and antigenicity of rVacA. Two ELISA methods were established to detect VacA expression in H pyloriisolates and the specific anti-VacA antibody in sera from 125 patients infected with H pylori.RESULTS: In comparison with the reported corresponding sequences, homologies of nucleotide and putative amino acid sequences of the cloned vacA gene were 99.82% and 100%, respectively. The constructed recombinant prokaryotic expression system efficiently produced rVacA. rVacA was able to combine with the commercial antibodies against whole cell of H pyloriand to induce the immunized rabbit to produce specific antibody with an immunodiffusion titer of 1:4. All tested H pyloriisolates carried vacA gene, but only 66.1% expressed Vac A protein. Of the serum samples tested,42.4% were positive for specific anti-VacA antibody.CONCLUSION: A prokaryotic expression system of H pylori vacA gene was successfully constructed. The expressed rVacA can be used to detect specific anti-VacA antibody in human and to prepare antiserum in animals. The high frequency of vacA gene in H pyloriisolates, but with a low frequency of VacA expression and specific anti-VacA antibody in H pyloriinfected patients implies that VacA is not an ideal antigen for H pylorivaccine.     

重组原核表达质粒PTrc99A-ureB/hlyE 的构建和表达

目的 构建表达幽门螺杆菌（Helicobacter pylori,Hp）尿素酶B亚单位（ureB）基因与大肠杆菌K-12株hlyE基因融合表达的原核表达质粒pTcr99A-hlyE.并表达。方法 用PCR扩增hlyE基因，经本科切连接反应将其克隆入重组原核表达质粒并测序，与GenBank中的核酸和蛋白序列进行BLAST分析，重组的阳性克隆经IPTG诱导培养，SDS-PAGE电泳进行表达分析，薄层扫描分析融合蛋白的含量。结果 对重组质粒进行酶切和PCR检测，证明构建了携带hlyE及ureB基因的重组原核表达质粒pTrc99A-ureB/hlyE,核酸序列测定及同源性分析证实所构建的原核表达质粒pTrc99A-ureB/hlyE中所含的Hp-ureB及hlyE与GeneBank中的Hp-ureB和hlyE序列的同源性分别为97.42%（1663/1707）、99%（910/918）。重组细菌JM109可表达约100kD的融合蛋白含量的15.5%。结论 构建并鉴定了原核表达质粒pTrc99A-hlyE并高效表达，为研究Hp口服疫苗奠定了基础。     

携带幽门螺杆菌hpaA基因减毒鼠伤寒沙门疫苗菌的构建

构建携带幽门螺杆菌（H.pylori)hpaA基因的重组活减毒鼠伤沙门疫苗菌。方法：用分子生物学方法将hpaA基因克隆入原核表达质粒pTrc99A,并进行核苷酸测序,重组质粒经再导入活减毒鼠伤寒沙门菌SL3261,提取重组菌苗质粒,聚合酶链反应（PCR）和酶切鉴定,筛选目的克隆。结果：经PCR和酶切证实,构建了携带hpaA基因（560bp)的重组核表达质粒pTrc99A-hpaA,并将后者成功转化活减毒鼠伤寒沙门菌SL3261。结论：S我建并鉴定了携带H.pylorihpaA基因的重组活减毒鼠伤寒沙门疫苗菌,为探索制备H.ylori口服份活疫苗奠定了基础。